Transcriptomic profiling of different responder types in adults after a Priorix® vaccination

Esther Bartholomeus, Nicolas De Neuter, Arvid Suls, George Elias, Sanne van der Heijden, Nina Keersmaekers, Hilde Jansens, Viggo Van Tendeloo, Philippe Beutels, Kris Laukens, Benson Ogunjimi, Geert Mortier, Pieter Meysman, Pierre Van Damme

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
29 Downloads (Pure)


Thanks to the recommendation of a combined Measles/Mumps/Rubella (MMR) vaccine, like Priorix®, these childhood diseases are less common now. This is beneficial to limit the spread of these diseases and work towards their elimination. However, the measles, mumps and rubella antibody titers show a large variability in short- and long-term immunity. The recent outbreaks worldwide of measles and mumps and previous studies, which mostly focused on only one of the three virus responses, illustrate that there is a clear need for better understanding the immune responses after vaccination. Our healthy cohort was already primed with the MMR antigens in their childhood. In this study, the adult volunteers received one Priorix® vaccine dose at day 0. First, we defined 4 different groups of responders, based on their antibody titers' evolution over 4 time points (Day 0, 21, 150 and 365). This showed a high variability within and between individuals. Second, we determined transcriptome profiles using 3'mRNA sequencing at day 0, 3 and 7. Using two analytical approaches, "one response group per time point" and "a time comparison per response group", we correlated the short-term gene expression profiles to the different response groups. In general, the list of differentially expressed genes is limited, however, most of them are clearly immune-related and upregulated at day 3 and 7, compared to the baseline day 0. Depending on the specific response group there are overlapping signatures for two of the three viruses. Antibody titers and transcriptomics data showed that an additional Priorix vaccination does not facilitate an equal immune response against the 3 viruses or among different vaccine recipients.

Original languageEnglish
Article number32165045
Pages (from-to)3218-3226
Number of pages9
Issue number16
Publication statusPublished - 3 Apr 2020

Bibliographical note

Copyright © 2020 Elsevier Ltd. All rights reserved.


Dive into the research topics of 'Transcriptomic profiling of different responder types in adults after a Priorix® vaccination'. Together they form a unique fingerprint.

Cite this